Site Editor
Thomas Flaig, MD
Thomas Flaig, MD
Posted: Wednesday, August 9, 2023
According to a study published in the journal BMC Cancer, researchers have identified three immunotherapy-related long noncoding RNAs (lncRNA), which they think may serve as independent prognostic biomarkers for bladder cancer. According to Wang et al, of the Cancer Hospital of China Medical University, Shenyang, “prognosis, immune cell infiltration, and immunotherapy efficacy were significantly different between high- and low-risk groups based on risk scores.”
“This study not only helps to promote our understanding of immunotherapy-related lncRNA in the prognosis of bladder cancer, but also provides new ideas for clinical immunotherapy and the development of novel therapeutic drugs for patients,” the investigators stated.
In their study, the researchers obtained genes with significant differences between anti–PD-L1 response and nonresponse from the IMvigor210 data set. These data were combined with bladder cancer expression data from The Cancer Genome Atlas cohort. Based on the data on long noncoding RNAs, the prognostic risk model of bladder cancer was constructed and verified by the Gene Expression Omnibus external data set. The characterization of immune cell infiltration and immunotherapy effects between high- and low-risk groups were then analyzed. Researchers predicted the competing endogenous RNA network and performed molecular docking of key target proteins.
“Additionally, we established a competing endogenous RNA network of lncRNA (SBF2-AS1)–miRNA (has-miR-582-5p)–mRNA (HNRNPA2B1). Targeting the protein HNRNPA2B1 identified the top eight small-molecule drugs with the highest affinity,” according to the investigators.
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
